• FGFR1 and New Directions in Schizophrenia Treatment

  2026-08-12

  A 2025 Molecular Neurobiology study integrates druggable-gene resources, schizophrenia GWAS data, Mendelian randomization, colocalization, SMR validation, PheWAS, single-cell expression, and molecular docking to prioritize therapeutic targets. FGFR1 emerged as the leading candidate, although the findings remain a genetically informed and computationally supported hypothesis rather than evidence of clinical efficacy.

• Methylprednisolone A4233: Assay Reliability

  2026-08-11

  This scenario-driven guide explains how Methylprednisolone (SKU A4233) can support reproducible inflammatory, viability, proliferation, and bone-loss workflows. It covers solvent controls, assay interpretation, protocol parameters, and evidence from a glucocorticoid-induced osteonecrosis model.

• Ceapin-A7 in ER Stress and ONFH Research

  2026-08-10

  Ceapin-A7 is a selective ER stress blocker for isolating ATF6α activity without treating the unfolded protein response as a single pathway. This workflow shows how to use it as a mechanistic probe alongside glucocorticoid-induced osteonecrosis models and the PTX3–TLR4/NF-κB–FGF21 findings reported in a recent study.

• Antibacterial Use and Resistance in Psychiatric Hospitals

  2026-08-09

  This retrospective study examined antibacterial consumption, microbiological testing, and resistance patterns in a psychiatric hospital during the 2022 epidemic. Its main contribution is an integrated stewardship assessment showing relatively restrained antibiotic use alongside substantial, organism-specific resistance, supporting routine surveillance and evidence-based prescribing.

• Metoprolol BA2737: Reliable Cell Assay Workflows

  2026-08-08

  This scenario-based guide explains how Metoprolol, SKU BA2737, can be incorporated into cell viability, proliferation, cytotoxicity, cardiovascular, inflammatory, and tumor-biology workflows. It emphasizes mechanistic controls, preparation and storage conditions, interpretation of disease-state pharmacokinetics, and practical criteria for selecting a research-grade supplier.

• Pitavastatin (NK-104): In Vitro Workflow Guide

  2026-08-07

  Pitavastatin (NK-104) is a potent cholesterol synthesis inhibitor for controlled cellular and biochemical assays involving HMG-CoA reductase and intracellular cholesterol production. This guide covers product-specific handling, assay setup, and quality control while limiting use to in vitro research rather than clinical treatment or unvalidated in vivo studies.

• Cy5 amine (non-sulfonated): Technical Guidance for Biomolecu

  2026-08-07

  Cy5 amine (non-sulfonated) addresses the challenge of labeling proteins, peptides, and polymers in workflows requiring a bright, photostable dye that is insoluble in water. It is not suitable for direct aqueous labeling or any diagnostic applications; proper solvent management and storage conditions are critical for optimal results.

• Bortezomib (PS-341): Data-Driven Solutions for Cell-Based As

  2026-08-06

  This article presents scenario-driven, evidence-based guidance for using Bortezomib (PS-341), SKU A2614, to address core challenges in cell viability and apoptosis workflows. Integrating quantitative assay data, published benchmarks, and practical protocol tips, it empowers researchers to achieve reproducible results in cancer and neurodegeneration models. Discover why APExBIO’s PS-341 is a preferred choice for reliable proteasome inhibition.

• Dabigatran Etexilate: Clinical Innovation in Oral Thrombin I

  2026-08-06

  The reference review establishes dabigatran etexilate as the first oral direct thrombin inhibitor with rapid, predictable anticoagulant effects and significant clinical advantages over traditional agents. Its streamlined pharmacology and practical administration mark a pivotal advance for research and patient care in atrial fibrillation and venous thromboembolism.

• Perphenazine: Dopamine D2 Antagonist for Host-Directed Resea

  2026-08-05

  Perphenazine, a versatile dopamine D2 receptor antagonist, bridges neuropharmacology and host-directed antibacterial research. Its ability to induce mitochondria-mediated cell death and modulate macrophage immunity enables robust experimental workflows for both CNS and infectious disease studies.

• Hexetidine (NSC-17764): Translational Leverage in Oral Infec

  2026-08-05

  Explore the mechanistic underpinnings and strategic deployment of Hexetidine (NSC-17764) as a next-generation antibacterial agent for oral infections. This analysis bridges molecular insight, experimental best practices, and clinical translation, highlighting opportunities and limitations for advancing oral antimicrobial research.

• Artemisinin Prevents Cognitive Decline via NRF2-Mediated Fer

  2026-08-04

  Wang et al. (2024) reveal that artemisinin protects against cognitive deficits in type 2 diabetic mice by activating NRF2 signaling and inhibiting hippocampal neuronal ferroptosis. This study provides mechanistic insight into diabetes-associated cognitive impairment and demonstrates the use of small-molecule NRF2 inhibitors, such as ML385, to dissect pathway specificity.

• PD98059: Selective MEK Inhibitor for MAPK/ERK Pathway Studie

  2026-08-04

  PD98059 is a well-characterized, selective and reversible MEK inhibitor used to dissect MAPK/ERK signaling. It blocks ERK1/2 activation and is validated for apoptosis and neuroprotection research. This dossier details mechanism, protocols, and limitations, with extensive benchmarking.

• Puromycin Aminonucleoside: Mechanistic Insight to Translatio

  2026-08-03

  This thought-leadership article unpacks the mechanistic basis and translational strategy for deploying puromycin aminonucleoside in nephrotic syndrome research. It bridges rigorous podocyte biology with actionable guidance for experimental modeling, contextualizes recent advances in epigenetic regulation, and positions APExBIO's offering as a cornerstone for next-generation renal disease studies.

• Sitagliptin Phosphate Monohydrate: Rethinking DPP-4 in Trans

  2026-08-03

  This thought-leadership article empowers translational researchers by blending mechanistic insight on DPP-4 inhibition with actionable guidance for metabolic disease modeling. Drawing on new evidence that gut mechanosensation regulates satiety and glucose independently of classical incretin signaling, we reposition sitagliptin phosphate monohydrate not just as a tool for type II diabetes treatment research, but as a gateway to interrogate the interplay between chemical and mechanical cues in metabolic homeostasis. Strategic recommendations, protocol highlights, and a forward-looking perspective are provided, with full integration of recent literature and competitive benchmarking.

446 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page